Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Is autoimmunity the Achilles' heel of cancer immunotherapy?

(2017) Carl H June et al.   NATURE MEDICINE

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

(2017) I. Puzanov et al.   Journal for ImmunoTherapy of Cancer

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

(2016) Rita Nanda et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations

(2016) Axel Hoos   NATURE REVIEWS DRUG DISCOVERY

Ipilimumab for Patients with Relapse after Allogeneic Transplantation

(2016) Matthew S. Davids et al.   NEW ENGLAND JOURNAL OF MEDICINE

Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy

(2015) Edward J Wyluda et al.   CANCER BIOLOGY & THERAPY

Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency

(2015) Tibor Bakacs et al.   IMMUNOBIOLOGY

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Regulatory T cells in the immunotherapy of melanoma

(2015) Zhengxiao Ouyang et al.   TUMOR BIOLOGY

Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma

(2015) G. de Velasco et al.   Cancer Immunology Research

Vaccines versus immunotherapy: Overview of approaches in deciding between options

(2015) Angus G Dalgleish   Human Vaccines & Immunotherapeutics

Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy

(2014) R. W. Joseph et al.   Cancer Immunology Research

PD-L1 Expression in Triple-Negative Breast Cancer

(2014) E. A. Mittendorf et al.   Cancer Immunology Research

Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1

(2013) Jörg B. Engel et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation

(2013) Rainer Storb et al.   JOURNAL OF CLINICAL ONCOLOGY

Control of minimal residual cancer by low dose ipilimumab activating autologous anti-tumor immunity

(2013) Shimon Slavin et al.   PHARMACOLOGICAL RESEARCH

Rare Cancer Successes Spawn 'Exceptional' Research Efforts

(2013) J. Kaiser   SCIENCE

Temperature Matters! And Why It Should Matter to Tumor Immunologists

(2013) E. A. Repasky et al.   Cancer Immunology Research

Old and new facts about hyperthermia-induced modulations of the immune system

(2012) Benjamin Frey et al.   INTERNATIONAL JOURNAL OF HYPERTHERMIA

Pharmacological modulation of GITRL/GITR system: therapeutic perspectives

(2011) Giuseppe Nocentini et al.   BRITISH JOURNAL OF PHARMACOLOGY

The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy

(2011) T. Fu et al.   CANCER RESEARCH

Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

(2010) B. C. Carthon et al.   CLINICAL CANCER RESEARCH

Anti-CTLA-4 therapy results in higher CD4+ICOShiT cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues

(2009) Hong Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

(2008) C. I. Liakou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA